



SourceOne Global Partners Launches Novel LysOmega® Longevity and Cognitive Health Formulation

LPC-rich omega-3® formulation uses the clinically proven VESIsorb® delivery system to support enhanced absorption and targeted DHA and EPA transport to the brain and retina.

CHICAGO, October 22, 2026 — SourceOne Global Partners today announced the launch of LysOmega®, a proprietary omega-3 formulation designed to increase levels of DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) omega-3 essential fatty acids in the brain and other vital organs via the MFSD2A transporter. The formulation is the result of a four-year research and product development program addressing the challenges omega-3 essential fatty acids face in crossing the blood-brain and blood-retina barriers.

“We have long understood the value of omega-3s. Emerging science now suggests that the way these essential fatty acids are delivered to key organs, including the brain, may be as important as the amount we take,” said Jesse Lopez, CEO and founder of SourceOne Global Partners.

- LysOmega® combines fish oil-derived DHA and EPA with phospholipids, choline in the form of lysophosphatidylcholine (LPC), and VESIsorb®.
- VESIsorb®, a Swiss-developed delivery system with more than 35 years of commercial use, has been clinically proven to improve the area under the curve (AUC) of omega-3 fatty acids in plasma by up to 26-fold, as demonstrated in a pharmaceutical omega-3 pharmacokinetic study.
- Prior research suggests VESIsorb® technology will deliver higher LPC-omega-3 levels in the plasma, leading to a higher concentration of LPC-omega-3 at the MFSD2A transporter surface, which may in turn result in higher concentrations of LPC-omega-3 in the central nervous system (CNS).

“Strategically utilizing a VESIsorb® technology-based formulation to address this multi-step omega-3 delivery from the intestines into the blood and then to the MFSD2A transporter in the right form gives our brand partners a powerful new foundation for product differentiation that supports potential applications in cognitive health, healthy aging, eye health, and reproductive health,” Lopez stated.

The LysOmega® launch represents a first-to-market opportunity with an LPC-rich omega-3® formula validated for compatibility with a clinically proven drug delivery system.

According to Lopez, SourceOne and its global technology partners confirmed the VESIsorb®-based formulation delivers reproducibility, homogeneity, and a smaller droplet size, resulting in a very low polydispersity index (PDI). The smaller droplet size (less than 100 nm) creates a larger surface area, improving absorption and bioavailability.

SourceOne Global Partners Launches Novel LysOmega® Longevity and Cognitive Health Formulation (cont'd)

In parallel with the product launch, a human clinical trial is scheduled to begin in the fourth quarter of 2026 with globally recognized omega-3 expert Michael Davidson, M.D., as lead researcher.

“The LysOmega® study is designed to generate human pharmacokinetic and biomarker data evaluating whether the formulation produces higher and more consistent circulating DHA and EPA levels, and greater CNS availability of DHA and EPA, than conventional omega-3 products,” Davidson said. “A particular focus is APOE4 carriers, roughly one in four people, who have a well-established increase in late-onset Alzheimer’s disease risk. Prior research suggests these carriers may experience reduced delivery of DHA across the blood-brain barrier and, in some supplementation trials, a more muted cognitive response than non-carriers. This groundbreaking study will evaluate SourceOne’s ability to address this unmet need with LysOmega®.”

LysOmega® is available exclusively through SourceOne Global Partners and will make its industry debut at SupplySide Global 2026 in Las Vegas. SourceOne welcomes inquiries from healthcare practitioners and nutrition brands interested in technical information, formulation opportunities, turnkey private-label softgel capsules, and commercial planning.



About SourceOne Global Partners

Since 2003, SourceOne Global Partners has provided health and wellness solutions to medical, healthcare, nutrition, and pharmacy brands worldwide. The company has established a global reputation for developing science-led formulations combined with innovative and patented delivery technologies to create differentiated solutions across nutritional supplements, pharmaceuticals, functional foods and beverages, and cosmetics. For more information, please visit SourceOneGlobal.com.